A H2020 research collaboration between Europe and Latin America developing cost-effective tools for the early diagnosis of hepatobiliary cancers
Erasmus MC, Rotterdam, NL
Joined February 2021
- Tweets93
- Following81
- Followers86
- Likes29
ESCALON retweeted
Our study @EscalonLiver on TLL1 and HCC in Latin America
pubmed.ncbi.nlm.nih.gov/3798…
@AnnalsofHepatol @MarcoArreseMD @diaz_ferrer1 @dcbalderramo @hccconnectinfo @LiverCancerConn @FundHepa
ESCALON retweeted
Great work by @MTappataMD @Spencer_GobleMD and @EscalonLiver looking at reported ancestry and HCC in Hispanics #TLM23
Direct correlation between non-european ancestry and NAFLD as a cause of HCC (next figure)
@UMN_GIHep @UMNews @dcbalderramo @MarcoArreseMD @diaz_ferrer1
ESCALON retweeted
Our study @EscalonLiver showing no impact of STAT4 SNP on HCC risk in Hispanics...unless they identify of European ancestry.
Key to assess ancestry!
Assessment of STAT4 Variants and Risk of Hepatocellular Carcinoma in Latin Americanshttps://pubmed.ncbi.nlm.nih.gov/37760499/
ESCALON retweeted
Our @EscalonLiver study validating GALAD for #HCC in Latin America and assessing ASAP score @HepCommJournal
Interesting data on non-cirrhotic HCC
Validation and optimization of AFP-based biomarkers for early HCC detection in Latin America and Europe pubmed.ncbi.nlm.nih.gov/3770…
ESCALON retweeted
ALEH Day 2. Presentation from Escalon. 2 poster and 1 oral presentation @EscalonLiver
ESCALON retweeted
ALEH. Bogotá Day 3. Excellent presentations from ESCALON members (2 poster and 1 oral presentation) @EscalonLiver @MarcoArreseMD Jhon Prieto @belupisano
ESCALON retweeted
Great presentation from @EnriquEvilu1978 related to the International CCA registry & Escalon participation. #ALEH 2023 @JesusMBanales @LIzquierdoSan
Congratulations Dr. Marco Arrese! @MarcoArreseMD
Congratulations team!
Great effort by our great team to publish a great paper w/the largest cohort of NAFLD in South America!
@dcbalderramo @EscalonLiver @Jo_akambaseMD @diaz_ferrer1
Epidemiology and risk factors for histopathologic characteristics of NAFLD in South Ame… pubmed.ncbi.nlm.nih.gov/3734…
ESCALON retweeted
🏆Check out the Editor's Choice #Review "Serum Biomarkers for the Prediction of Hepatocellular Carcinoma"
👥Authors: @JoseDebesMD, @pabloromagnoli et al. @ErasmusMC @IucbcI
🔗Link here: mdpi.com/2072-6694/13/7/1681
ESCALON retweeted
Fighting against Hepatitis B in Sarayacu Ecuadorian Amazon. Beatiful group and great job !!@USFQ_Ecuador @EscalonLiver @NO_hep @hepatitis @heugenioespejo
Congratulations to the team Bañales!
Just 🍿!😃
🍀Liquid Biopsy 🩸protein biomarkers for Cholangiocarcinoma!
🔓👉 journal-of-hepatology.eu/art…
Accurate, fast & cost-effective test to 🔍:
👉risk of CCA (PSC👫)
👉early diagnosis
👉prognosis
🩸Biomarkers 🪞tumor cells (scRNAseq)
#livertwiter
ESCALON retweeted
Local but important work on HBV in Argentina by our awesome collaborators @belupisano & V. Re
Genotype variation between acute and chronic HBV, HIV+ & -, mutation variants and HDV
gt seems to matter!
Acute and chronic HBV infection in central Argentina: pubmed.ncbi.nlm.nih.gov/3669…
Our meeting in Chile has ended but the last year of ESCALON is about to start! #EUHorizon2020
ESCALON retweeted
It was an honor to present at the @EscalonLiver meeting. I am impressed by the international team that has assembled to tackle hepatobiliary cancer in South America!
@diaz_ferrer1 talks about Systemic Treatment and Survival of HCC patients without cirrhosis – at Pirque, Chile
And the last talk by @pabloromagnoli highlights the advances in aflatoxin measurements, immune infiltrates in NASH patients that precedes HCC and Erasmus+ interactions – at Pirque, Chile
